Choosing the right patent portfolio strategy will aid in protecting your valuable biotech intellectual property.
References
KSR Int'l Co. v. Teleflex, Inc., 550 U.S. 398 (2007)
Wang, S.-J. Nat. Biotechnol. 27, 1125–1126 (2009).
In re Fisher. 421 F.3d 1365 (2005).
Ariad Pharmaceuticals, Inc. v. Eli Lilly and Co. 598 F.3d 1336 (2010).
Simon, B.M. & Scott, C.T. Nat. Biotechnol. 29, 229–230 (2011).
Kimberly-Clark Corp. v. Johnson & Johnson. 745 F.2d 1437 (1984).
Elias, S. & Stim, R. Patent, Copyright & Trademark (Nolo, Berkeley, CA, 2003).
Goldenson, D. Nat. Biotechnol. 27, 538–541 (2009).
Palazzoli, F. et al. Nat. Biotechnol. 29, 593–597 (2011).
Granstrand, O. The Economics and Management of Intellectual Property (Edward Elgar, Cheltenham, UK, 1999).
Wang, S.-J. Hum. Vaccin. 7, 569–573 (2011).
Wang, S.-J. Hum. Vaccin. 7, 474–476 (2011).
Wang, S.-J. Nat. Biotechnol. 26, 519–522 (2008).
Boyer, H.W. & Cohen, S.N. US Patent 4,237,224 (1980).
Goldstein, H. IEEE Spectr. 43, 44–47 (2006).
Le, J. & Vilcek, J. Lab. Invest. 61, 588–602 (1989).
Vilela, E.G. et al. World J. Gastroenterol. 18, 872–881 (2012).
Kamm, M.A. et al. Inflamm. Bowel Dis. 17, 2366–2391 (2011).
Present, D.H. et al. Ann. Intern. Med. 111, 641–649 (1989).
Acknowledgements
This work is supported in part by the National Science Council (NSC 101-2325-B-075-003, 100-2221-E-075-001, 101-2221-E-075-001) and Taipei Veterans General Hospital (V101C-061, V102C-068), Republic of China.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Wang, SJ. Patent portfolios for biotech inventions. Nat Biotechnol 31, 501–503 (2013). https://doi.org/10.1038/nbt.2598
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2598
- Springer Nature America, Inc.
This article is cited by
-
Commercialization of regenerative-medicine therapies
Nature Reviews Bioengineering (2023)